Replies to post #19248 on Positron Corporation (POSC)

[Medtrade77]

Bracco adds customers when existing customer discontinues. Zero growth rate until additional capacity exists.

Zevacor is not ahead of schedule but behind with investor questioning economics.

Same people at the source telling same stories.

Proof of industry returning to growth mode only comes from added supply, other pharma, new applications.